title: Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia.
abstract: OBJECTIVE
  To discuss the clinical effects of Western medicine therapy assisted by Ginkgo biloba tablet (GBT) on patients with vascular cognitive impairment of none dementia (VCIND).
  
  
  METHODS
  A total of 80 patients with VCIND were divided into two groups randomly: Conventional treatment group (control group) and combined treatment group. Conventional treatment group was given conventional treatment with anti-platelet aggregation. In this group, 75 mg aspirin was given three times a day for 3 months. While in combined treatment group, 19.2 mg GBT was given three times a day for 3 months together with conventional treatment (anti-platelet aggregation drugs). Montreal cognitive assessment (MoCA) and transcranial Doppler (TCD) were used to observe changes of cognitive ability and cerebral blood flow in VCIND patients before and after treatment in both groups. Then the clinical data were analyzed so as to compare the efficacy in two groups.
  
  
  RESULTS
  After 3 month-treatment in combined treatment group, the scores of executive ability, attention, abstract, delayed memory, orientation in the MoCA were significantly increased compared with those before treatment and those in control group after treatment. Besides, blood flow velocity of anterior cerebral artery increased significantly than that before treatment and that in control group after treatment.
  
  
  CONCLUSIONS
  GBT tablet can improve the therapeutic efficacy as well improve cognitive ability and cerebral blood flow supply of patients with VCIND.
authors: Department of Traditional Chinese Medicine, People's Hospital of Zhengzhou, Zhengzhou, Henan Province, 450003, China. shijin_zhang@126.com
authors: Shi-Jin
authors: SJ
authors: Zhang
authors: Zhan-You
authors: ZY
authors: Xue
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D001783:Blood Flow Velocity; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000150:complications* / Q000503:physiopathology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D020441:Ginkgo biloba; D006801:Humans; D008297:Male; D008516:Medicine, Chinese Traditional; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011581:Psychological Tests; D016896:Treatment Outcome; D000096983:Ginkgo Extract
chemical_list: D001241:Aspirin; D002317:Cardiovascular Agents; D010936:Plant Extracts; D010975:Platelet Aggregation Inhibitors; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract